Sangamo BioSciences (SGMO)

Company Description

Sangamo BioSciences is focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and genome editing. The Company has ongoing Phase II clinical trials to evaluate the safety and efficacy of a novel ZFP Therapeutic® for the treatment of HIV/AIDS. SGMO’s other therapeutic programs are focused on monogenic diseases, including hemophilia, Huntington’s disease and hemoglobinopathies such as beta-thalassemia and sickle cell anemia. SGMO’s core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). Engineering of ZFPs that recognize a specific DNA sequence enables the creation of sequence-specific ZFP Nucleases (ZFNs) for gene modification and ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function. The company has entered into a strategic collaboration with Shire AG to develop therapeutics for hemophilia, Huntington’s disease and other monogenic diseases and has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation.


501 Canal Boulevard
Richmond, California 94804
United States



Get BioInvest's perspective on Sangamo's CEO

Latest Company News

Analyst's Predictions on Brookdale Senior Living Inc. (BKD), Sangamo ... StockNewsJournal - 8 hours ago Sangamo Therapeutics, Inc. (NASDAQ:SGMO), maintained return on investment for the last twelve months at -44.77, higher than what Reuters data shows regarding industry's average. Is It Overvalued? Look at the P/S Ratio: Brookdale Senior Living Inc. (BKD ... - AllStockNews [...]
Tue, Jun 27, 2017 2:15:00 PM, Continue reading at the source
Sangamo Therapeutics Announces Closing Of Public Offering Of Common Stock And ... PR Newswire (press release) - Jun 26, 2017 RICHMOND, Calif., June 26, 2017 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO) announced today the closing of its public offering of 10,000,000 shares of common stock at a price to the public of $7.25 per share. [...]
Mon, Jun 26, 2017 8:03:00 PM, Continue reading at the source
Sangamo Therapeutics Inc (SGMO)'s Stock Is Buy After Making 52-Week High Weekly Register - Jun 26, 2017 Investors sentiment decreased to 1.15 in Q4 2016. Its down 0.06, from 1.21 in 2016Q3. It dived, as 17 investors sold Sangamo Therapeutics Inc shares while 31 reduced holdings. 18 funds opened positions while 37 raised stakes. 39.96 million shares or ... Sangamo Therapeutics (SGMO) Reaches $9.45 52-Week High, Onconova Therapeutics ... - Herald KS [...]
Mon, Jun 26, 2017 5:14:00 PM, Continue reading at the source
The Unified Clarity of The Technical Chart For Sangamo Therapeutics, Inc ... NY Stock News - Jun 22, 2017 Sangamo Therapeutics, Inc. (SGMO) has created a compelling message for traders in the most recent trading. That message has grown stronger as the technical chart setup has developed into a more composite picture for the stock. [...]
Thu, Jun 22, 2017 7:30:00 PM, Continue reading at the source
Here's Why Sangamo Therapeutics Rose as Much as 11.7% Today Motley Fool - Jun 22, 2017 Shares of biopharmaceutical company Sangamo Therapeutics (NASDAQ:SGMO) rose nearly 12% this morning after a new analyst took over coverage of the stock at Jefferies. 3 Stocks to Watch on Wednesday: Carmax, Inc (KMX), Adobe Systems Incorporated ... - Sangamo Therapeutics, Inc. (SGMO) Exposed Via Its Technical Chart - NY Stock News [...]
Thu, Jun 22, 2017 4:30:00 PM, Continue reading at the source
Biotech Movers: Sangamo, Epizyme, Revance - Jun 21, 2017 Shares of Sangamo Therapeutics Inc. (SGMO) were down nearly 11% to $7.30 on Wednesday, June 21. The Richmond, Calif.-based firm said it has priced an underwritten public offering of 10 million shares at $7.25 apiece, which would generate gross ... [...]
Wed, Jun 21, 2017 1:30:00 PM, Continue reading at the source
Sangamo Therapeutics Inc: Biotech prices stock deal at deep discount Times of India - Jun 21, 2017 (Updates, adds pricing information). ** Sangamo Therapeutics shares down >11 pct premarket as biotech prices its overnight follow-on. [...]
Wed, Jun 21, 2017 1:07:00 PM, Continue reading at the source
Sangamo Therapeutics Announces Proposed Public Offering of Common Stock PR Newswire (press release) - Jun 20, 2017 RICHMOND, Calif., June 20, 2017 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO) announced today that it has commenced an underwritten public offering of shares of its common stock. Zacks: Analysts Anticipate Sangamo Therapeutics Inc (SGMO) to Announce -$0.27 ... - The Cerbat Gem Hot Stocks Report: Sangamo Therapeutics, Inc. (SGMO), Destination XL Group ... - Post Analyst [...]
Tue, Jun 20, 2017 7:52:00 PM, Continue reading at the source
Sangamo Therapeutics And Pfizer Announce That SB-525 Investigational ... PR Newswire (press release) - Jun 7, 2017 RICHMOND, Calif., June 7, 2017 /PRNewswire/ -- Sangamo Therapeutics, Inc. (NASDAQ: SGMO) and Pfizer Inc. (NYSE: PFE) announced today that the European Medicines Agency (EMA) has granted orphan medicinal product designation (OMPD) to ... Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Trading Up – Insiders Selling, Short ... - Highlight Press Zacks Investment Research Downgrades Sangamo Therapeutics Inc (SGMO) to Sell - The Cerbat Gem [...]
Wed, Jun 07, 2017 11:26:00 AM, Continue reading at the source
Sangamo: Despite Pfizer Deal, Valuation Is Not Justified Seeking Alpha - Jun 5, 2017 Sangamo Therapeutics, Inc. (NASDAQ:SGMO) has been in the medicine development business for over 20 years and has nothing much to show for it except a recent collaboration deal with Pfizer (NYSE:PFE). [...]
Mon, Jun 05, 2017 9:00:00 PM, Continue reading at the source